Quantcast
Last updated on April 24, 2014 at 14:55 EDT
Drug Treatment And Weight Loss Can Restore Vision Loss Study

Drug Treatment And Weight Loss Can Restore Vision Loss: Study

NIH/National Eye Institute An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of...

Latest placebo Stories

2014-04-23 12:29:10

MINNEAPOLIS, April 23, 2014 /PRNewswire-USNewswire/ -- Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. Both studies involve drugs that are aimed at preventing migraine attacks from occurring, rather than stopping the attacks once they have started. These studies are the first to test monoclonal antibodies for the prevention of...

2014-04-23 09:37:13

In patients with idiopathic intracranial hypertension and mild vision loss, the use of the drug acetazolamide, along with a low-sodium weight-reduction diet, resulted in modest improvement in vision, compared with diet alone, according to a study in the April 23/30 issue of JAMA, a neurology theme issue. Idiopathic intracranial hypertension (IIH) is a disorder primarily of overweight women of childbearing age, characterized by increased intracranial pressure with its associated signs and...

2014-04-17 23:10:15

New e-booklet by Nashville therapist Bonnie Lenihan tells how to end panic disorder, a typically chronic and debilitating condition, by eliminating what causes it. Nashville, Tennessee (PRWEB) April 17, 2014 Nashville therapist Bonnie Lenihan announced today's launch of "How to End Panic Disorder: A Simple Guide," a trailblazing new e-booklet that untangles the mystery of what causes panic disorder and lays out simple steps for resolving it. Written for persons who have...

2014-04-17 14:37:35

In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with effects being significant in the lateral femorotibial compartment but not in the central femorotibial compartment. Results published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), showed that...

2014-04-10 10:13:27

Meta-analysis finds relationship improvement has beneficial effects similar to some common treatments A meta-analysis of studies that investigated measures designed to improve health professionals' interactions with patients confirms that such efforts can produce health effects just as beneficial as taking a daily aspirin to prevent heart attack. In contrast to previous such reviews, the current report from the Empathy and Relational Science Program at Massachusetts General Hospital (MGH)...

2014-04-07 13:07:48

The Effects of Aspirin in Gestation and Reproduction (EAGeR) medical trial has found that, in general, low-dose aspirin is not beneficial for future pregnancy outcomes in women with prior pregnancy loss. However, in women with one pregnancy loss within the previous 12 months, there did appear to be a benefit. Jean Wactawski-Wende, PhD, professor in the Department of Epidemiology and Environmental Health in the School of Public Health and Health Professions at the University at Buffalo,...

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...

2014-04-02 23:33:55

New study by researchers Dr. Eric Finzi and Dr. Norman E. Rosenthal published in the Journal of Psychiatric Research May 2014 edition reports that patients injected with onabotulinumtoxinA demonstrated substantial improvement - 52% - in their depressive symptoms. Washington, DC (PRWEB) April 02, 2014 In the largest randomized, double-blind, placebo controlled study to date on the effect of OnabotulinumtoxinA (known as Botox) on depression, researchers found that more than half of subjects...

2014-04-02 12:20:48

Commonly used neurological medication proves successful at blocking brain's reward system triggers Relapse is the most painful and expensive feature of drug addiction—even after addicted individuals have been drug-free for months or years, the likelihood of sliding back into the habit remains high. The National Institute on Drug Abuse estimates that 40 to 60 percent of addicted individuals will relapse, and in some studies the rates are as high as 80 percent at six months after...

2014-03-31 08:29:05

MELBOURNE, Australia, March 31, 2014 /PRNewswire/ -- Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. Prana's PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients, as measured using PiB-PET Standardized Uptake Value...